Enzon Pharmaceuticals Inc (ENZN OTCQX) stock market data APIs
$0.104
0(0%)
as of March 26, 2025
Enzon Pharmaceuticals Inc Financial Data Overview
Enzon Pharmaceuticals, Inc., together with its subsidiaries, does not have significant operations. Previously, it sells its patented drug product, PegIntron. It also had a marketing agreement with Micromet AG relating to the Vicineum drug; and a licensing agreement regarding SC Oncaspar and certain other drugs. The company was formerly known as Enzon, Inc and changed its name to Enzon Pharmaceuticals, Inc. in December 2002. Enzon Pharmaceuticals, Inc. was incorporated in 1981 and is headquartered in Cranford, New Jersey.
Prev. Close
0.104
Open
0.104
High
0.104
Low
0.104
52 wk Range
0.06-0.24
Market Cap
8 906 K
Shares Outstanding
74 215 K
Revenue
26 000
Beta
0.262
Why to choose EODHD?
Prices start at $19.99
24/7 Live support
Robust, powerful and reliable data
API Simplicity of a few lines of code
Try our APIs
with free plan!
Or get access to advanced financial data starting only $19.99
TRY NOW
Get Enzon Pharmaceuticals Inc data using free add-ons & libraries
Get Enzon Pharmaceuticals Inc Fundamental Data
Enzon Pharmaceuticals Inc Fundamental data includes:
- Net Revenue: 26 000
- EBITDA:
- Earnings Per Share:
- Income Statements
- Balance Sheets
- Cash flows
Plans with Fundamental data
Starting from
$
59.99
/mo.
End-of-day & Earnings data
What’s included:
- Latest Release: 2025-03-18
- EPS/Forecast: NaN
What’s included:
- End of Day, Intraday and Live APIs
- Splits
- Dividends
Enzon Pharmaceuticals Inc News
New
Enzon Pharmaceuticals, Inc. CEO Andrew Rackear to Retire; Richard L. Feinstein, Enzon’s CFO, to Assume Position of CEO and Remain CFO
CRANFORD, N.J., Jan. 04, 2021 (GLOBE NEWSWIRE) -- Enzon Pharmaceuticals, Inc. (OTC:ENZN) announced today that Andrew Rackear has communicated to the Board his intent to retire from his role as the C...
Enzon Pharmaceuticals Announces Results of Rights Offering
CRANFORD, N.J., Oct. 21, 2020 (GLOBE NEWSWIRE) -- Enzon Pharmaceuticals, Inc. (the “Company” or “Enzon”) (OTC:ENZN) announced the results of its rights offering following the expiration of ...
Enzon Pharmaceuticals Announces Key Dates for Rights Offering
CRANFORD, N.J., Sept. 15, 2020 (GLOBE NEWSWIRE) -- Enzon Pharmaceuticals, Inc. (the “Company” or “Enzon”) (OTC:ENZN) announced today the record date and expected subscription period for its ...
Enzon Pharmaceuticals, Inc. Announces Postponement of 2020 Annual Meeting
CRANFORD, N.J., Sept. 02, 2020 (GLOBE NEWSWIRE) -- Enzon Pharmaceuticals, Inc. (the “Company” or “Enzon”) (OTC:ENZN) today announced that its 2020 annual meeting of stockholders (the “Annu...
Try our APIs
with free plan!
Or get access to advanced financial data starting only $19.99
TRY NOW
- Flexibility: No long-term commitments, just a minimum of one month
- Instant access: Get your API key and instructions within seconds of subscribing
- Price stability: Locked-in rates for subscribed users, never changing
All-In-One
$99.99/mo.
What’s included:
- API Calls per Day: 100 000/day
- API Requests per Min.: 1000/minute
- Type of Usage: Personal use
Data access:
Historical EOD, Fundamental, Real-Time, Intraday, Live (Delayed), Technical & Screener APIs, News Feed, 40 000 Stock Logos and many more. See a full list.
